![Erin Lavelle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erin Lavelle
Direktor/Vorstandsmitglied bei
JADE BIOSCIENCES, INC.
Vermögen: - $ am 30.06.2026
Profil
Ms. Erin M.
Lavelle is an Independent Director at Jade Biosciences, Inc. and an Independent Director at Avalyn Pharma, Inc. She is on the Board of Directors at Jade Biosciences, Inc., Jade Biosciences, Inc. (United States) and Avalyn Pharma, Inc. Ms. Lavelle was previously employed as an Executive VP, Chief Operating & Financial Officer by Eliem Therapeutics, Inc., an Independent Director by Neoleukin Therapeutics, Inc., a Chief Operating Officer by Lundbeck Seattle BioPharmaceuticals, Inc., and a General Manager by Amgen, Inc. She also served on the board at Vitaeris, Inc. She received her undergraduate degree from Yale University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AVALYN PHARMA INC -.--% | 30.04.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Erin Lavelle
| Unternehmen | Position | Beginn |
|---|---|---|
| JADE BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 28.04.2025 |
| AVALYN PHARMA INC. | Direktor/Vorstandsmitglied | 01.07.2024 |
Ehemalige bekannte Positionen von Erin Lavelle
| Unternehmen | Position | Ende |
|---|---|---|
| CLIMB BIO, INC. | Finanzdirektor/CFO | 10.03.2023 |
| ALDER BIOPHARMACEUTICALS, INC. | Geschäftsführer | 01.02.2020 |
| AMGEN INC. | Corporate Officer/Principal | 01.03.2018 |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Develops new treatment options for chronic inflammatory diseases | Direktor/Vorstandsmitglied | - |
| NEUROGENE INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Erin Lavelle
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
83
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Avalyn Pharma Inc.
 Avalyn Pharma Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops inhaled therapies to treat rare respiratory & interstitial lung diseases | Health Technology |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Develops new treatment options for chronic inflammatory diseases | Health Technology |
Eliem Therapeutics, Inc.
 Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Develops de novo – therapeutic proteins to treat serious immunological disorders, including cancer and autoimmunity | Health Technology |
Aerovate Therapeutics, Inc.
 Aerovate Therapeutics, Inc. BiotechnologyHealth Technology Provides gene therapy services | Health Technology |
